The family of a deceased plasma donor and public health advocates are seeking a re-examination of the circumstances surrounding the death of Rodiyat Alabede at a Grifols facility in Winnipeg.

一名已故血漿捐贈者的家屬與公共衛生倡導者，正尋求重新調查 Rodiyat Alabede 在溫尼伯 Grifols 設施死亡 surrounding 的情況。

The incident occurred on October 25, 2025, involving Rodiyat Alabede, a 22-year-old student. According to the chief medical examiner's autopsy, the cause of death was cardiac arrest precipitated by dilated cardiomegaly. While Health Canada and the Manitoba chief medical examiner have asserted that the fatality was temporally coincident with, but not caused by, the plasma donation process, representatives for the family contend that the physiological stress of the procedure may have exacerbated the decedent's pre-existing cardiac condition.

該事件發生於 2025 年 10 月 25 日，涉及一名 22 歲的學生 Rodiyat Alabede。根據首席法醫的驗屍結果，死因為擴張性心臟病引起的心臟驟停。雖然加拿大衛生部與曼尼托巴省首席法醫堅稱，死亡時間雖與血漿捐贈過程重疊，但並非由該過程引起，但家屬代表主張，該程序的生理壓力可能加劇了死者原有的心臟狀況。

Significant discrepancies have been identified between the autopsy report and a medical summary provided by Health Canada to parliamentary committees. Specifically, the autopsy records the collection of 200 milliliters of plasma prior to the cardiac event, whereas the Health Canada summary cites 586 milliliters. Furthermore, while Health Canada's summary characterized the Taylor Avenue clinic as compliant with standard operating procedures, a December inspection report detailed systemic deficiencies. These included inadequate staff training regarding machine alarms and failures in maintaining accurate records.

驗屍報告與加拿大衛生部提供給議會委員會的醫療摘要之間存在顯著差異。具體而言，驗屍記錄顯示在心臟事件發生前採集了 200 毫升血漿，而加拿大衛生部的摘要則記載為 586 毫升。此外，儘管加拿大衛生部的摘要將 Taylor Avenue 診所描述為符合標準操作程序，但 12 月的檢查報告詳細列出了系統性缺陷，包括員工對機器警報的培訓不足以及紀錄維護不準確。

Institutional oversight of Grifols, the sole major commercial plasma collector in Canada, has come under scrutiny following a second fatality at a separate Winnipeg site in January 2026. In response to recurring systemic deficiencies identified across multiple inspections, Health Canada imposed restrictive licensing conditions on April 1, including donor limits and enhanced supervision. Despite these regulatory actions, advocates argue that the failure to investigate the intersection of the decedent's pathology and the donation process constitutes a lapse in the duty of care.

作為加拿大唯一的主要商業血漿採集商，Grifols 在 2026 年 1 月於溫尼伯另一處場地發生第二起死亡事件後，其機構監管受到質詢。針對多次檢查中發現的重複性系統缺陷，加拿大衛生部於 4 月 1 日實施了限制性許可條件，包括捐贈者限額及加強監督。儘管採取了這些監管行動，倡導者認為，未能調查死者病理與捐贈過程之間的交集，構成了照護義務的缺失。

The situation remains unresolved as advocates petition the federal government to reopen the investigation and suspend Grifols' operating licenses.

由於倡導者正請願聯邦政府重新開啟調查並暫停 Grifols 的經營許可，情況仍未解決。